Apr 14, 2010

Molecular determinants of the cardiometabolic phenotype

Endocrine, Metabolic & Immune Disorders Drug Targets
Lisa de las FuentesVíctor G Dávila-Román

Abstract

The metabolic syndrome represents a clustering of risk factors that has been shown to predict adverse cardiovascular outcomes. Although the precise mechanisms contributing to the cardiometabolic syndrome (CMS) remain poorly defined, accumulating evidence identifies two intersecting candidate pathways responsible for inflammation and energy homeostasis in the pathophysiology that underlie cardiometabolic traits. Although currently no pharmacologic interventions specifically target CMS, future drug development efforts should attempt to capitalize on molecular nodes at the intersections of these pathways in the CMS.

  • References
  • Citations2

References

  • We're still populating references for this paper, please check back later.

Mentioned in this Paper

Drug Development
Biochemical Pathway
NUC1 PPAR
Cardiovascular Diseases
Metabolic Syndrome X
Saturated Fat
Risk Reduction
Inflammation
Physiopathological
Energy Homeostasis

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.